Louise Goksøyr

Louise Goksøyr serves as a Guest Researcher within the Department of Immunology and Microbiology at the University of Copenhagen's Faculty of Health and Medical Sciences. Her work centers on capsid virus-like particle (cVLP) vaccine platforms for therapeutic and prophylactic applications across diverse disease areas including oncology, infectious diseases, and neurodegenerative disorders.

Her research specializes in modular cVLP vaccine design targeting specific molecular pathways. Key projects include PCSK9-targeted vaccines for cardiovascular disease, HER2-directed immunotherapies for breast cancer, SARS-CoV-2 vaccine development, and $$\\text{IL-}1\\beta$$-targeted approaches for inflammatory skin conditions. She also investigates $$\\alpha\\text{-synuclein}$$ oligomerization mechanisms in Parkinson's disease, bridging vaccine technology with neurodegenerative disease diagnostics.

Analysis of her 2022-2025 publications reveals consistent innovation in cVLP platform engineering, with applications spanning preclinical models (mice, rainbow trout) to human clinical trials. Her work demonstrates strong interdisciplinary integration of immunology, molecular biology, and biotechnology, particularly in adapting vaccine platforms for cancer, infectious diseases, and protein aggregation disorders.

Louise Goksøyr collaborates extensively within the VLPVAC research group at the University of Copenhagen, working closely with principal investigators including Adam F. Sander, Ali Salanti, and Thor G. Theander. Her research outputs show significant translational impact, with multiple studies receiving media coverage and citations across academic and clinical domains.